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Abstract
Background: Development of countermeasures to bioterrorist threats such as those posed by
the smallpox virus (variola), include vaccination and drug development. Selective activation of
nucleoside analogues by virus-encoded thymidine (dThd) kinases (TK) represents one of the most
successful strategies for antiviral chemotherapy as demonstrated for anti-herpes drugs. Vaccinia
virus TK is a close orthologue of variola TK but also shares a relatively high sequence identity to
human type 2 TK (hTK), thus achieving drug selectivity relative to the host enzyme is challenging.
Results: In order to identify any differences compared to hTK that may be exploitable in drug
design, we have determined the crystal structure of VVTK, in complex with thymidine 5'-
triphosphate (dTTP). Although most of the active site residues are conserved between hTK and
VVTK, we observe a difference in conformation of residues Asp-43 and Arg-45. The equivalent
residues in hTK hydrogen bond to dTTP, whereas in subunit D of VVTK, Asp-43 and Arg-45 adopt
a different conformation preventing interaction with this nucleotide. Asp-43 and Arg-45 are
present in a flexible loop, which is disordered in subunits A, B and C. The observed difference in
conformation and flexibility may also explain the ability of VVTK to phosphorylate (South)-
methanocarbathymine whereas, in contrast, no substrate activity with hTK is reported for this
compound.
Conclusion: The difference in conformation for Asp-43 and Arg-45 could thus be used in drug
design to generate VVTK/Variola TK-selective nucleoside analogue substrates and/or inhibitors
that have lower affinity for hTK.
Background
Thymidine kinases form part of the salvage pathway for
pyrimidine deoxyribonucleotide synthesis. TKs are
expressed in a variety of organisms from human to bacte-
ria as well as in a number of viruses. The reaction catalysed
by TK involves the transfer of a γ-phosphoryl moiety from
ATP to 2'deoxy-thymidine (dThd) to produce thymidine
5'-monophosphate (dTMP). Certain TKs, such as those
from herpes simplex virus type 1 (HSV-1) and varicella
zoster virus (VZV) have, in addition, thymidylate kinase
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activity allowing the conversion of dTMP to thymidine 5'-
diphosphate (dTDP). TKs can be classified into two types
which differ in several respects [1]. Type 1 TKs are of
higher molecular weight, typically around 40 kDa, and are
active as homodimers. This subfamily contains the HSV1,
HSV2 and VZV TKs, and also mitochondrial TK.
TKs of type 2 include those from poxviridae such as vac-
cinia virus (VV) and variola virus, [2], as well as from
human [3] hTK, (human type II thymidine kinase 1) and
mouse [4]. Type 2 TKs have a smaller polypeptide chain
compared to type 1, being of ~25 KDa but form homote-
tramers. They are sensitive to the feedback inhibitors
dTDP or dTTP, which are generated at the end of the met-
abolic pathway [5]. Type 2 TKs have a much narrower sub-
strate specificity compared to type 1 TKs and only
phosphorylate 2'deoxyuridine (dU) and/or dThd [6]. For
example, the antiherpetic drug (E)-5-(2-bromovinyl)-
dUrd (BVDU) [7] is not metabolised by the type 2 TKs (i.e.
cytosolic TK) in contrast to the type 1 TKs (i.e. mitochon-
drial TK, HSV-1 TK) which can phosphorylate a variety of
(5-substituted) nucleoside analogues including BVDU.
Moreover, HSV-1 and HSV-2 TK can even recognize (acy-
clic) purine nucleoside analogues such as acyclovir and
ganciclovir [8]. This difference in substrate specificity is
the basis of some selective antiviral drug action as vali-
dated by the activation of nucleoside analogues by certain
herpes virus TKs. Moreover, herpes TKs are also being
studied as suicide genes in a combined gene/chemother-
apy strategy to treat cancer [9].
The World Health Organisation declared in 1980 that
smallpox had been eradicated. Since then, routine inocu-
lation with the vaccinia virus vaccine was discontinued,
resulting in minimal or even non-existent smallpox
immunity in the human population [10]. Today, the
potential use of smallpox virus as a biological weapon is a
major cause for concern, particularly in the context of cur-
rent low levels of herd immunity to the virus. Addition-
ally, the re-emergence of monkeypox virus infection in
humans (mainly in Africa but some cases have also been
reported in the United States [11]), has lead to the stock-
piling of smallpox vaccine (VV), mainly in developed
countries [12]. Nevertheless, some adverse reactions
which are sometimes lethal, following vaccination have
been reported [13-15]. VV should neither be given to preg-
nant women for example, nor to people who have a weak-
ened immune system, skin problems like eczema, heart
problems or to children under one year old [12]. Thus,
specific anti-variola drugs need to be developed as a mat-
ter of priority, particularly for widespread use in a bioter-
rorism emergency, as well as for specific cases of
unwanted contamination by VV or complications like
eczema vaccinatum or progressive vaccinia. Such drugs
would be of particular importance if more virulent strains
of variola virus were engineered using genetic modifica-
tions. Worryingly, one of the only anti-variola drugs avail-
able, cidofovir [16], has been reported to be inefficient
against several pox viral strains [17].
Herpes virus TKs have been exploited in the selective acti-
vation of nucleoside analogues such as acyclovir, which
have spawned a series of highly successful anti-herpetic
drugs [18]. The same approach may therefore be applica-
ble in the case of orthopoxviruses. Further understanding
of the structural differences between type 1 and 2 TKs
would also greatly help to improve and/or create specific
drugs against the type 1 TK. Indeed, a drug would be selec-
tive if it is preferentially metabolised by the type 1 and not
the type 2 TKs or vice versa. Thus gathering structural infor-
mation about both TK types is likely to be of great impor-
tance in assisting drug design. So far, HSV1 TK [19,20] and
VZV TK [21] structures have been solved, whilst for type 2
TK, the structure of human cytosolic thymidine kinase
[22,23] and the TK of Ureaplasma ureolyticum recently
became available [22,24]. Moreover, determining the
structure of different type 2 TKs could help as in the case
of orthopox viruses, to design virus TK-specific drugs.
Recently, 5-(2-amino-3-cyano-5-oxo-5,6,7,8-tetrahydro-
4H-chromen-4-yl)-1-(2-deoxy-pentofuranosyl)pyrimi-
dine-2,4-(1H,3H)-dione has been shown to be phophor-
ylated specifically by vaccinia and cowpox virus TKs [25].
We report here for the first time, the structure of VVTK,
one of the smallest type 2 TKs known, in complex with
dTTP at 3.1 Å resolution. This work will be of use, in com-
bination with the previous type 2 TK structures, to design
or improve type 1 TK-selective drugs as well as drugs that
show selectivity against orthopox virus TKs such as VVTK
or Variola TK.
Results and discussion
VVTK enzyme kinetics
Assessment of the activity of VVTK to phosphorylate vari-
ous nucleosides showed its ability to recognize both dCyd
and dThd amongst the natural substrates. The efficiency of
dCyd phosphorylation was, however, much less (<5%)
compared to that with dThd (Fig. 1). In contrast, purified
cytosolic TK showed a poor, if any, recognition of dCyd
(data not shown). VVTK also efficiently converted the thy-
midine analogues araT and AZT to their corresponding
mono-phosphates whereas no substrate activity was
observed for the purine nucleosides araA, dA, dG and
CdA. In this respect, VVTK behaves more similarly to
cytosolic TK (Fig. 1). Also, dTTP inhibits the phosphoryla-
tion of dThd (1 μM) by VVTK with an IC50 (50% inhibi-
tory concentration) of 14 ± 4.0 μM, whereas the
corresponding IC50 for cytosolic TK was markedly lower
(2.8 ± 0.5 μM).BMC Structural Biology 2006, 6:22 http://www.biomedcentral.com/1472-6807/6/22
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Overall structure of VVTK
The quaternary structure of VVTK (Fig. 2a and 2b) is tetra-
meric. which is similar to that of hTK [22,23]. hTK shares
66% amino acid sequence identity with VVTK, showing a
conserved fold amongst species (Fig. 2b). The four VVTK
subunits within the tetramer are identical apart from a
flexible loop (residues 40 to 60) situated on the surface. In
the other type 2 TK structures [22-24], the equivalent loop
is either not visible or appears to be in a different confor-
mation from one monomer to the other, indicating that
this flexibility is common to Type 2 TKs. It has been
inferred that this loop might be involved in phosphoryl
donor interaction [24].
As found in other type 2 TKs, VVTK has a central α/β
domain structure consisting of six parallel β-strands sur-
rounded by helices (Fig. 2a). Above the α/β domain, a
zinc-binding domain is present, the latter belongs to the
structural zinc-binding class [26]. Although no zinc was
added during purification or crystallization, the metal is
present in the structure and coordinated to four cysteines.
This metal is believed to play a structural role, stabilising
the adjacent loop, or lasso domain, involved in nucleo-
side binding via residues Tyr-166 and Arg-150. The
cysteines involved in zinc binding are also found in the
hTK, whilst in the case of the Ureaplasma enzyme, the last
cysteine is substituted by a histidine [22].
Active site structure of VVTK
VVTK crystals grew in the presence of dTTP, the feedback
inhibitor of the pathway. The binding of dTTP in VVTK is
similar to that observed in the hTK structure. The phos-
phates of dTTP bind to the α/β domain, whereas the
thymine base and the deoxyribose bind between the lasso
domain and the α/β domain (Figs. 2a, 3c). The thymine
moiety is bound to the backbone of the protein via resi-
dues Phe-113, Ile-157 and 159. Thus this region of the
enzyme appears unsuitable for use in designing species-
selective ligands as no side-chain contacts are present (Fig.
2c).
Whilst most of the VVTK active site residues are conserved
and superimpose well with the human TK, nevertheless,
some significant differences are apparent. In the VVTK
active site Ser-148 replaces the equivalent residue in hTK,
Thr-163, a serine being also present in UuTK. Welin et al,
proposed that this position, relatively close to the 5-
methyl group of dTTP, could be used in the design of
selective nucleoside analogues for UuTK versus the
human enzyme. Indeed the pocket around the 5-methyl
group of dTTP is slightly larger compared to the pocket of
hTK, so substitutions at the 5 position of dThd could be
explored [24]. Based on the same argument, these kinds of
analogues may also be effective with VVTK and UuTK but
not hTK.
A further important difference in the VVTK active site is
the conformation of Asp-43 and Arg-45 (Fig. 3b). The
equivalent residues in hTK are in close contact with the 3'-
oxygen of the deoxyribose and to the β-phosphoryl oxy-
gen of dTTP respectively, whereas they are not in the case
of VVTK. Asp-43 and Arg-45 are only observed in the
VVTK subunit D, they are disordered in the other three
subunits, indicating the flexible nature of this loop. Nev-
ertheless, the dTTP still adopts the same conformation in
each subunit as observed in the human enzyme. We thus
can infer that Asp-43 and Arg-45 may not be crucial for
the binding of dTTP, otherwise this ligand would either
not stay bound to the active site or would shift position. It
has been proposed that Arg-60 in hTK (Arg-45 in VVTK)
may act to stabilize the transition state of the reaction
[22]. From the VVTK structure, it appears that the confor-
mation of this residue has to change to allow contact with
the substrate and hence the reaction to occur. The flexibil-
ity of this loop region also implies that more space is
available in the VVTK active site compared to hTK. Clearly,
using bulkier groups at the 3- and 5-positions in the pyri-
midine ring of the dThd molecule should be investigated
for the rational design of novel, specific drugs against
VVTK. Modifying the sugar moiety would also be a worth-
while approach to pursue in the design of further ana-
logues.
Ligand specificity of VVTK
Thymidine analogues such as (South)-methanocarbath-
ymine ((S)-MCT) and (North)-methanocarbathymine
((N)-MCT) (Fig. 4) have been studied as antiviral agents
against orthopox and herpes viruses. For orthopox viruses,
such as variola and vaccinia viruses, ((N)-MCT has potent
antiviral activity whilst ((S)-MCT) does not [27,28]. Due
Histogram showing substrate activity of certain nucleosides  with VVTK Figure 1
Histogram showing substrate activity of certain nucleosides 
with VVTK.
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a. Diagram showing one VVTK monomer complexed with dTTP and magnesium Figure 2
a. Diagram showing one VVTK monomer complexed with dTTP and magnesium. α-helices are shown in red/grey, β-strands 
are in blue/grey with loops in gold. dTTP is in standard atom colors and the magnesium ion is in blue. b. Diagram showing the 
superimposition of α-carbons of hTK (grey) and VVTK. Each VVTK subunit is shown in different colors (green/red/yellow/
blue). c. Stereo-diagram of the VVTK active site showing residues that interact with dTTP and magnesium. Protein side-chains 
and main-chain carbon atoms are in grey, main-chain N and O atoms are in blue and red respectively). dTTP is drawn in stand-
ard atom colors with the magnesium ion in greenBMC Structural Biology 2006, 6:22 http://www.biomedcentral.com/1472-6807/6/22
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a. Stereo-diagram highlighting the positions ofresidues studied in site-directed mutagenesis experiments of VVTK Figure 3
a. Stereo-diagram highlighting the positions ofresidues studied in site-directed mutagenesis experiments of VVTK. Side chains 
subjected to mutation are shown in grey. b. Stereo-diagram showing the different conformations of residues Asp-43 and Arg-
45 in subunit D of VVTK and the equivalent hTK residues colored in cyan. c. Diagram showing the final 2fo-fc map contored at 
1σ for dTTP and magnesium. Color coding for the protein secondary structure is as for Fig 2a.BMC Structural Biology 2006, 6:22 http://www.biomedcentral.com/1472-6807/6/22
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to the pseudo-ring conformation, ((S)-MCT) has been
reported to be the preferred substrate of herpes TKs,
whereas ((N)-MCT) is preferred by the cellular DNA
polymerases [29]. Prichard et al suggested that ((N)-MCT)
could also be phosphorylated by type 2 TKs from cowpox
and vaccinia viruses [28], whereas Smee et al inferred that
orthopoxvirus TKs are not responsible for the formation
of phosphorylated ((N)-MCT) [27]. It has also been
shown that hTK has a weak affinity for ((N)-MCT) and
essentially no affinity for ((S)-MCT) [29]. ((S)-MCT)
inhibits growth of HSV1 TK transduced osteosarcoma
cells [30], thus hTK alone could not be involved in drug
activation. The MCT activity seems to be highly dependent
on the particular cell line, which is thus a consideration in
validating a particular result. Thus the test system ulti-
mately of most relevance to human therapy would
involve primates [27].
Nevertheless, HPLC activity assays have shown that ((S)-
MCT) can be phosphorylated by VVTK [23], thus MCT
modeled in the VVTK active site structure could be used as
a basis for drug design. The superimposition of (S)-MCT
and dTTP shows that the thymine ring and the sugar/
pseudo-sugar match very well. As the (S)-MCT can be
phosphorylated, this suggests that the conformation of
the dThd moiety of dTTP has a very similar conformation
to the dThd substrate in VVTK. This has been confirmed
by the recent structure of UuTK complexed with dThd
(PDB code: 2B8T) [24]. The fact that VVTK is able to phos-
phorylate (S)-MCT suggests that a larger sugar moiety can
fit into the active site. Such a difference in substrate specif-
icity between hTK and VVTK might be due to the flexibility
of the loop containing Arg-45 (Arg-60 in hTK).
Further suggestion that the plasticity of the VVTK active
site relative to hTK is indicated by the selective phosphor-
ylatioin by VVTK compared to hTK of the bulky molecule
5-(2-amino-3-cyano-5-oxo-5,6,7,8-tetrahydro-4H-
chromen-4-yl)-1-(2-deoxy-pentofuranosyl)pyrimidine-
2,4-(1H,3H)-dione. The latter drug showed a minimal
toxicity to uninfected cells and inhibited the replication of
vaccinia and cowpox virus [25]. Fan et al, suggested that
orthopoxvirus kinases are more promiscuous than previ-
ously believed. Indeed their substrate specificity seems
broader than cellular kinases, thus these enzymes could
be exploited in a similar manner to the herpes TKs.
Relating VVTK mutagenesis and structural studies
Prior to the determination of any crystal structure of a type
2 TK, some mutational studies had been reported on
VVTK. It has been shown that residue Asp-82 participates
in the binding of magnesium [31] (Fig. 3a) and that the
loss of a negatively charged residue at this position alters
the ability of VVTK to transfer the γ-phosphate moiety of
ATP to dThd. It was suggested that Asp-82 is not involved
in ATP binding but rather aids its correct orientation for
nucleophilic attack. In the VVTK structure, Asp-82 is
indeed orientated towards the metal ion and its distance
from the magnesium ion varies from one subunit to
another (from 3.2 to 3.7 Å).
VVTK mutants Ser18Thr and Thr19Ser (Fig. 3a) [32] have
also been studied, and showed an increased activity of
3.7-fold and 1.4-fold, respectively. The equivalent to Thr-
19 is conserved in most type 2 TKs although not in the
case of Ureaplasma, where it is substituted by an alanine
and thus is unlikely to be essential for catalysis. Indeed,
VVTK mutated in this position to the bulkier residues Asn
Structure of (north)-methanocarbathymine (left) and (south)-methanocarbathymine (right) Figure 4
Structure of (north)-methanocarbathymine (left) and (south)-methanocarbathymine (right).BMC Structural Biology 2006, 6:22 http://www.biomedcentral.com/1472-6807/6/22
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or Arg retains significant activity (~27% of wild-type).
Even a Pro-19 mutant retains 10% of wild-type VVTK
activity. Thr-19 is not directly involved in dTTP binding
but may have a role in ATP binding. As yet no type 2 TK
has been solved with bound ATP, hence it is difficult to
assess the importance of this residue. The Ser18Thr
mutant shows a greater enhancement of enzyme activity
(~3.8-fold) than does Thr19Ser and indeed in our struc-
ture, Ser-18 forms hydrogen bonds via its main-chain
nitrogen to a γ-phosphate oxygen and via its side-chain
oxygen to the magnesium and a γ-phosphate oxygen. Thus
Ser-18 would appear more crucial for enzyme catalysis
than Thr-19. Although Ser-18 is conserved in the hTK
structure (Ser-33) it is conservatively substituted for thre-
onine in UuTK (Thr26). The methyl group of the Thr-26
side-chain is in van der Waals contact with Ile-30 (3.8 Å).
It is thus possible that replacing the serine by threonine
could stabilize the side-chain oxygen in a preferential con-
formation for substrate binding, which may explain the
increased activity of the Ser18Thr mutant VVTK.
Finally, mutational studies have been reported on Gln-
114 [33] (Fig. 3a). The authors inferred that Gln-114 par-
ticipates in the feedback inhibition by dTTP since this
mutant TK could bind dTTP yet feedback inhibition was
abolished. Interestingly, Gln-114 is not in contact with
dTTP, and more surprisingly, it is located on the surface of
the tetramer. The effect of mutating Gln-114 to either His
or Asp would only be to break the hydrogen bond with
the adjacent Lys. In this case, the abolition of the feedback
inhibition could only be explained by a destabilization of
the loop which is in close contact with the dTTP molecule.
However, the mutation does not apparently affect the
VVTK activity under standard conditions, thus either the
binding of substrates dThd and ATP are not disrupted by
this mutation, or if they are, the decrease in apparent
affinity is compensated for as a result of an increase in cat-
alytic rate. To clarify this, further experiments would be
needed to determine the kcat and Km of each mutant.
Conclusion
In conclusion, the work reported here provides the first
structure of VVTK. Even though showing similarity to the
other type 2 TK structures, the detailed comparison of the
active site points to principles for designing specific inhib-
itors of VVTK relative to hTK, mainly by using the fact that
the deoxyribose appears able to accept bulkier/modified
substituents. This result is consistent with Birringer et al's
report of (S)-MCT being phosphorylated by VVTK whilst
not being a substrate for hTK [23]. Knowledge of the resi-
dues involved in ligand binding of type 2 TKs by structure
comparison, might also assist in the design of specific
drugs against type 1 TKs.
Methods
Protein purification
The pET-16b-VVTK (derived from Novagen pET-16b)
expression plasmid coding for an N-terminal His6-tagged-
VVTK was transformed into Rosetta(DE3)pLysS for pro-
tein expression. The cells were grown in a 40 ml Luria
Broth starter culture supplemented with 50 μg/ml carben-
icillin and 34 μg/ml chloramphenicol, overnight, with
shaking at 37°C. The culture was then diluted 1/100 into
4 l of LB and grown at 37°C until the A600 reached 0.7. iso-
propyl-beta-D-thiogalactopyranoside was added to 1 mM
and the induction was carried out for 3 hours at the same
temperature. The cells were harvested by centrifugation
and the pellets were resuspended in buffer A (50 mM
sodium inorganic phosphate pH 7.8, 300 mM NaCl). The
cells were disrupted by sonication and the supernatant,
following clarification by centrifugation, was applied to a
5 ml nickel chelating column (Hi-trap chelating Column,
GE Healthcare) pre-equilibrated with buffer A. VVTK was
eluted with buffer A + 500 mM imidazole. Fractions con-
taining VVTK were applied to a Superdex S200 16/60 gel
filtration column pre-equilibrated with 50 mM Tris-HCl
pH 7.8 and 200 mM NaCl. The fractions containing VVTK
were pooled and buffer exchanged against 20 mM Tris-
HCl pH 8 and finally, concentrated to 22 mg/ml. The
purification protocol produced on average 25 mg of VVTK
per litre of culture.
Crystallisation and data collection
Thymidine triphosphate, dithiothreitol and MgCl2 were
added to VVTK for initial screening in several Hampton,
Wizard and Emerald kits in a total of 768 conditions. A
Cartesian Technologies pipetting robot was used to set up
100 + 100 nl sitting drops in Greiner 96-well plates which
were placed in a TAP storage vault [19]. After optimisa-
tion, crystals grew in 2–7% polyethylene glycol 3350, 5
mM MgSO4 and 50 mM MES pH6.5. Even though the
crystals were small (50 μm in the longest dimension),
they were suitable for data collection.
X-ray diffraction data were collected at 100 K in-house
using a Rigaku MicroMax 007 generator Cu Kα radiation
source and a MAR 345 imaging plate detector (MAR
Research). Crystals diffracted to a resolution limit of 3.1 Å.
Images were indexed and integrated with DENZO, whilst
data were merged using SCALEPACK [34]. The crystals
belong to space group P31 with unit cell lengths of a = b =
63.3, c = 166.4 (Å), and contained four VVTK subunits
within the asymmetric unit. Detailed statistics for X-ray
data collection are given in Table 1.
The VVTK crystal structure was solved by molecular
replacement using MOLREP [35] with the coordinates of
hTK (PDB code 1W4R) [23] as the search model. Refine-
ment was carried out using cycles of manual rebuildingBMC Structural Biology 2006, 6:22 http://www.biomedcentral.com/1472-6807/6/22
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with COOT [36], followed by NCS restrained refinement
using CNS [37] and REFMAC5 [38] with TLS [39]. Real
space electron density averaging applied to the four mole-
cules in the VVTK crystal asymmetric unit was carried out
using the program GAP (D. I. Stuart, J. M. Grimes & J. M.
Diprose, unpublished). Density for the dTTP ligand was
fitted as appropriate and refined. The final refinement
parameters of Rwork and Rfree were 25.7 and 28.9% respec-
tively (Table 1). Structural superpositions were performed
with SHP [40], and figures were drawn using PYMOL
(DeLano, W.L. (2002) DeLano Scientific, San Carlos, CA,
USA). The coordinates of VVTK together with structure
factors have been deposited in the protein data bank (PDB
code 2J87).
Enzyme assays
Thymidine kinase assays were carried out in a 50 μl reac-
tion mixture containing : 50 mM Tris_HCl pH7.6, 0.1 mg/
ml BSA, 2.5 mM γ-32 [P] ATP, 5 mM MgCl2, 5 mM dithio-
threitol, and nucleoside analogs. In the assays with dThd,
2'-deoxycytidine, 2'-deoxyadenine and 2'-deoxyguanos-
ine, 1 mM of nucleoside analog was used, in the other
assays, 150 μM of nucleoside was used. The samples were
incubated for 30 min at 37°C. The substrate specificity of
the purified enzyme was assayed by thin layer chromatog-
raphy. The autoradiography was scanned with a "Biorad
Personal Molecular Image FX" and the was interpreted
with "Quantity one" software also from Biorad.
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